Johnson & Johnson (JNJ)

LGBTQ equality
A (95)
Screens
Advertising
Alcohol
Cannabis
Carbon emissions intensity
Coal
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Music
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Oppressive governments
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Single-use plastic
Sugar
Tobacco
Undermining US elections
Weapons
Impact

Cause JNJ
Peer rank
LGBTQ equality

Name Rating
Loading...
Screens
Advertising
Alcohol
Cannabis
Carbon emissions intensity
Coal
Deforestation - financing
Deforestation - supply chain
Discrimination controversies
Environmental controversies
Factory farming
Fast food
Firearms
For-profit health care
Fossil fuel
Fur
Gambling
Genetic engineering
Human trafficking
Interest-based products
Interest-bearing debt
Interest-bearing securities
Music
Norges Bank exclusion list
Northern Ireland (Macbride)
North Korea
No SBTI commitment
Nuclear
Oil and gas
Oppressive governments
Pork
Pornography
Predatory lending
Prison involvement
Privacy breaches
Single-use plastic
Sugar
Tobacco
Undermining US elections
Weapons
Top metrics
Sample of top metrics driving Johnson & Johnson's rating for LGBTQ equality (A, relative to other companies). Hover or click on a bubble for more info. See details for all metrics in table below
Loading...
All metrics
Metrics used to rate Johnson & Johnson for LGBTQ equality. Click on a metric for more info
Metric Source Data Normalized
Loading...

Data status

Summary statistics on data used to rate Johnson & Johnson for LGBTQ equality

...

of potential metrics used

...

unique data

...

peer-average data

4 days ago

last updated

...

company filings data

...

government data

...

Ethos research

...

independent organization data
Controversies
Controversies associated with Johnson & Johnson. Click on a controversy for more info
Title Date Severity
Loading...
* Indicates data is an average of peer group, or industry if peer data not available. Used when data for company not available.
Normalized scores are relative to other companies. Learn more about our ratings methodology
Note that all controversies information is based on publicly-available information.
JNJ Price
$177.33
Last available end-of-day price. Full disclosure
Revenue
$96.04 billion
Market cap
$448.33 billion
Public/private
Public
Hypothetical historical growth of $10,000
Historical performance
Company
Founded
1886
Employees
141,700
Sector
Healthcare
Industry
Pharmaceuticals & Biotech
Peer group
Drug Manufacturers - Major
Headquarters
New Jersey, United States
Share classes
JNJ
Mission
To keep people well at every age and every stage of life. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere.
Description
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Material causes
Ethos considers the following causes material for Johnson & Johnson, based on its industry peer group Drug Manufacturers - Major. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.